Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: A possible link

Pediatric Diabetes

Volumn 7, Issue 1, 2006, Pages 51-59

  Mylona Karayanni, Christina ^a   Gourgiotis, Dimitrios ^a   Bossios, Apostolos ^a   Kamper, Elli F ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adhesion molecules; Glutathione peroxidase; Lipid hydroperoxides; NO stable metabolites; Type 1 diabetes mellitus

Indexed keywords

CELL ADHESION MOLECULE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; INSULIN; LIPID HYDROPEROXIDE; NITRATE; NITRITE; PADGEM PROTEIN; TETRANECTIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DIABETIC ANGIOPATHY; DISEASE COURSE; DISEASE DURATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; MALE; METABOLIC PARAMETERS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; THROMBOCYTE ACTIVATION;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LECTINS, C-TYPE; LIPID PEROXIDES; MALE; NITRIC OXIDE; OXIDATIVE STRESS; P-SELECTIN;

EID: 33646688164     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-543X.2006.00147.x     Document Type: Article

References (55)

1. Brownlee B. Biochemistry and molecular cell biology of diabetic complications. Nature 2001: 414: 813-820.
2. Cullen P, Von Eckardstein A, Souris S, Schulte H, Assmann G. Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1999: 1: 189-198.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive insulin treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
4. McN ally PG, Raymond NT, Swift PG, Hearnshaw JR, Burden AC. Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med 1993: 10: 906-908.
5. Hink U, Li H, Mollnau H et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001: 88: E14-E22.
6. Tesfamariam B. Free radicals in diabetic endothelial dysfunction. Free Rad Bio Med 1991: 10: 339-352.
7. Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med 2002: 251: 69-76.
8. Petersen S, Due AV, Valnickova Z, Oury TD, Crapo JD, Enghild JJ. The structure of rabbit extracellular superoxide dismutase differs from the human protein. Biochemistry 2004: 43: 14275-14281.
9. Takahashi K, Avissar N, Whitin J, Cohen H. Purification and characterisation of human plasma glutathione peroxidase, a selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys 1987: 256: 677-686.
10. Bjornstedt M, Xue J, Huang W, Akesson B, Holmgren A. The thioredoxin and glutaredoxin system are efficient donors to human plasma glutathione peroxidase. J Biol Chem 1994: 269: 29382-29384.
11. Yamamoto Y, Takahashi K. Glutathione peroxidase isolated from plasma reduces phospholipids hydroperoxides. Arch Biochem Biophys 1993: 305: 541-545.
12. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: Mechanisms and therapeutic potential. Review. Cardiovasc Res 2002: 55: 250-260.
13. Brownlee M. Negative consequences of glycation. Metabolism 2000: 49: 9-13.
14. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycolsylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993: 90: 6434-6438.
15. Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000: 49: 1939-1945.
16. Shono T, Ono M, Izumi H et al. Involvement of the transcription factor NF-kappa B in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996: 16: 4231-4239.
17. Lu D, Maulik N, Moraru II, Kreutzer DL, Das DK. Molecular adaptation of vascular endothelial cells to oxidative stress. Am J Physiol 1993: 264: C715-C722.
18. Roebuck KA, Rahman A, Lakshminarayanan V, Janakidevi K, Malik AB. H2O2 and tumor necrosis factor-alpha activate intercellular adhesion molecule 1 (ICAM-1) gene transcription through distinct cis-regulatory elements within the ICAM-1 promoter. J Biol Chem 1995: 270: 18966-18974.
19. Ng CK, Deshpande SS, Irani K, Alevriadou BR. Adhesion of flowing monocytes to hypoxia-reoxygenation-exposed endothelial cells: Role of Rac1, ROS, and VCAM-1. Am J Physiol Cell Physiol 2002: 283: C93-C102.
20. Niwa K, Inanami O, Ohta T, Ito S, Karino T, Kuwabara M. p38 MAPK and Ca2+ contribute to hydrogen peroxide-induced increase of permeability in vascular endothelial cells but ERK does not. Free Radic Res 2001: 35: 519-527.
21. Lusis AJ. Atherosclerosis. Nature (London) 2000: 407: 233.
22. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994: 8: 504-512.
23. McEven RP. Selectins. Curr Opin Immunol 1994: 6: 75-84.
24. Holtet TL, Graversen JH, Clemmensen I, Thogersen HC, Etzerodt M. Tetranectin, a trimeric plasminogen-binding C-type lectin. Protein Sci 1997: 6: 1511-1515.
25. Graversen JH, Lorentsen RH, Jacobsen C et al. The plasminogen binding site of the C-type lectin tetranectin is located in the carbohydrate recognition domain, and binding is sensitive to both calcium and lysine. J Biol Chem 1998: 273: 29241-29246.
26. Graversen JH, Jacobsen C, Sigurskjold BW et al. Mutational analysis of affinity and selectivity of kringle tetranectin interaction. Grafting novel kringle affinity onto the tetranectin lectin scaffold. J Biol Chem 2000: 275: 37390-37396.
27. Mogues T, Etzerodt M, Crystal H, Engelich G, Graversen JH, Hartshorn KL. Tetranectin binds to the kringle 1-4 form of angiostatin and modifies its functional activity. J Biomed Biotechnol 2004: 2: 73-78.
28. Lorentsen RH, Graversen JH, Caterer NR, Thogersen HC, Etzerodt M. The heparin-binding site in tetranectin is located in the N-terminal region and binding does not involve the carbohydrate recognition domain. Biochem J 2000: 347: 83-87.
29. Borregaard N, Christensen L, Bejerrum OW, Birgens HS, Clemmensen I. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase. J Clin Invest 1990: 85: 408-416.
30. Nielsen H, Clemmensen I, Kharazmi A. Tetranectin: A novel secretory protein from human monocytes. Scand J Immunol 1993: 37: 39-42.
31. Christensen L. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS 1992: 26 (Suppl): 1-39.
32. Kluft C, Los P, Clemmensen I. Calcium-dependent binding of tetranectin to fibrin. Thromb Res 1989: 55: 233-238.
33. Wewer UM, Ibaraki K, Schjorring P, Durkin ME, Young MF, Albrechtsen R. A potential role for tetranectin in mineralization during osteogenesis. J Cell Biol 1994: 127: 1767-1775.
34. Clemmensen I, Lund LR, Christensen L, Andreasen PA. A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur J Biochem 1991: 195: 735-741.
35. Wewer UM, Iba K, Durkin ME et al. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev Biol 1998: 200: 247-259.
36. Jensen BA, Clemmensen I. Plasma tetranectin is reduced in cancer and related to metastasia. Cancer 1988: 62: 869-872.
37. Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol 1997: 24: 262-268.
38. Kamper EF, Kopeikina LT, Mantas A, Stefanadis C, Toutouzas P, Stavridis J. Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem 1998: 35: 400-407.
39. Kopeikina LT, Kamper EF, Mantas A, Kremastinos D, Stavridis J. Plasma tetranectin levels in patients with unstable and stable angina. Fibrinolysis Proteolysis 1998: 12: 353-359.
40. Kamper EF, Kopeikina LT, Karajiannis CH, Gourgiotis D, Karpathios TH, Stavridis JC. Tetranectin, soluble P-selectin and VCAM-1 in the plasma of children with insulin-dependent diabetes mellitus. Fibrinolysis Proteolysis 1999: 13: 148-153.
41. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967: 70: 158-169.
42. Scheuber SB, Rybak JN, Rösli C, Neri D, Elia G. Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics 2004: 4: 1737-1760.
43. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004: 53: 3226-3232.
44. Manka D, Forlow SB, Sanders JM et al. Critical role of platelet P-selectin in the response to arterial injury in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004: 24: 1124-1129.
45. Malamitsi-Puchner A, Sarandakou A, Dafogianni C, Tziotis J, Bartsocas CS. Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus. Growth Factors 1999: 17: 75-79.
46. Zhou XJ, Vaziri ND, Wang XQ, Silva FG, Laszik Z. Nitric oxide synthase expression in hypertension induced by inhibition of glutathione synthase. J Pharmacol Exp Ther 2001: 296: 252-259.
47. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Baylis C. Peroxynitrite versus nitric oxide in early diabetes. Am J Hypertens 2003: 16: 761-766.
48. Davi G, Chiarelli F, Santilli F et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. Circulation 2003: 107: 3199-3203.
49. Toivonen AM, Kulmala P, Savola K, Akerblom HK, Knip M. Soluble adhesion molecules in pre-clinical type 1 diabetes: A prospective study. Diabetologia 2003: 46: 492-495.
50. Francois M, Kojda G. Effect of hypercholesterolemia and of oxidative stress on the nitric oxide-cGMP pathway. Neurochem Int 2004: 45: 955-961.
51. Guzik TJ, West NEJ, Black E et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000: 86: e85-e90.
52. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005: 25: 1512-1518.
53. Rueckschloss UJ, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells antioxidative potential of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy. Circulation 2001: 104: 1767-1772.
54. Li WG, Stoll LL, Rice JB et al. Activation of NAD(P)H oxidase by lipid hydroperoxides: Mechanism of oxidant-mediated smooth muscle cytotoxicity. Free Radic Biol Med 2003: 34: 937-946.
55. Furnkranz A, Schober A, Bochkov VN et al. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol 2005: 25: 633-638.